first generic glp 1 Connecticut could make history as state to manufacture its own GLP-1 drugs glp1 #diabetes #medication #t2dm |

At the new studys conclusion, researchers found that the reduction in major adverse cardiac event risk found during their 2023 study was similar regardless of how much a study participants weight was at the start of the trial and how much weight they lost over the first 4.5 months of taking semaglutide

For many treatments, our consults are completed asynchronously via photo uploads and written intake forms

The ADAs consensus since 2018 explicitly states: Consider a GLP-1 receptor agonist before insulin in most patients who need injectable therapy due to their efficacy, lower hypoglycemia risk, and weight loss advantage ( [10] ) ( [11] )

In addition to the STEP trials, real-world studies and independent reviews further support the effectiveness of a variety of GLP-1 receptor agonists for weight management, with weight loss typically ranging from 5% to 15% depending on dose, duration, and adherence.28,29 A retrospective, noninterventional drug utilization cohort study in the United Kingdom evaluated the use of different varieties of liraglutide for weight management purposes.30 Among 604 individuals using Saxenda (liraglutide 3 g) and 4,853 individuals using Victoza (liraglutide 1.2 mg/1.8 mg), most were able to achieve 5% weight loss within 24 weeks.30 Emerging data on tirzepatide has also shown even greater weight reductions (up to 21% over 72 weeks) over other GLP-1s, as well as improved quality of life.31,32 Together, these findings show the support GLP-1s can provide in long-term weight management